Skip to main content
. Author manuscript; available in PMC: 2014 Jul 1.
Published in final edited form as: Medicine (Baltimore). 2013 Jul;92(4):223–243. doi: 10.1097/MD.0b013e31829d08f9

Table 6.

Outcomes of juvenile myositis categorized by autoantibody

Disease
Course*
Total

(n=312)
Anti-synthetase
(n=15)
Anti-SRP

(n=6)
Anti-Mi-2

(n=10)
Anti-p155/140
(n=107)
Anti-MJ

(n=74)
MSA and MAA
Negative
(n=100)
Significant
Differences
Chronic 161 (51.6) 10 (66.7) 6 (100.0) 4 (40.0) 70 (65.4) 34 (45.9) 37 (37.0) SRP vs. None3
, MJ vs.
p155/1401,
p155/140 vs.
None4
Polycyclic 74 (23.7) 3 (20.0) 0 (0.0) 4 (40.0) 24 (22.4) 19 (25.7) 24 (24.0)
Monocyclic 77 (24.7) 2 (13.3) 0 (0.0) 2 (20.0) 13 (12.1) 21 (28.4) 39 (39.0)
Total (N=374) Anti-synthetase
(n=19)
Anti-SRP (n=6) Anti-Mi-2 (n=11) Anti-p155/140
(n=131)
Anti-MJ (n=86) MSA and MAA
Negative
(n=121)
n (%) Miss-
ing
n (%) Miss-
ing
n (%) Miss-
ing
n (%) Miss-
ing
n (%) Miss-
ing
n (%) Miss-
ing
n (%) Miss-
ing
Ever
hospitalized
191
(53.5)
17 13
(68.4)
0 6
(100.0)
0 6
(54.5)
0 58
(46.4)
6 52
(62.7)
3 56
(49.6)
8 SRP vs.
p155/1403,
SRP vs. None2,
MJ vs.
p155/1402
Calcinosis 120
(32.2)
1 2
(10.5)
0 0
(0.0)
0 2
(18.2)
0 40
(30.5)
0 32
(37.2)
0 44
(36.7)
1 Synth vs. MJ2,
Synth vs. None2
Wheelchair use 64
(17.7)
13 4
(22.2)
1 5
(83.3)
0 3
(27.3)
0 19
(14.8)
3 20
(23.8)
2 13
(11.4)
7 Synth vs. SRP2,
SRP vs. Mi-22,
SRP vs. MJ3,
SRP vs.
p155/1404,
SRP vs. None4,
MJ vs. None2
Mortality 12
(3.4)
18 3
(16.7.)
1 0
(0.0)
0 0
(0.0)
1 3
(2.4)
6 1
(1.3)
6 5
(4.3)
4 Synth vs. MJ2,
Synth vs.
p155/1402

Abbreviations: SRP = signal recognition particle; MSA = myositis-specific autoantibodies; MAA = myositis-associated autoantibodies.

*

Total n for disease course differs because cases with an undefined disease course have been removed.

Significant differences

1

p < 0.05

2

p < 0.01

3

P < 0.005

4

p < 0.001

Abbreviations of autoantibodies: Synth = anti-synthetase; MJ = anti-MJ; p155/140 = anti-p155/140; SRP = anti-signal recognition particle; Mi-2 = anti-Mi-2.